Journal of Clinical Endocrinology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Commentary - Journal of Clinical Endocrinology Research (2022) Volume 5, Issue 6

Mammalian fetal stem cells with regular and preeclamptic births differentially produce vascular endothelial growth factor (VEGF), endocrine system

Chung Ha*

Department of Anatomy, Biochemistry, and Physiology, Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA

*Corresponding Author:
Chung Ha
Department of Anatomy, Biochemistry, and Physiology
Burns School of Medicine, University of Hawaii at Manoa
Honolulu, HI, USA

Received: 26-Nov-2022, Manuscript No. AAJCER-22-85061; Editor assigned: 28-Nov-2022, PreQC No. AAJCER-22-85061 (PQ); Reviewed: 07-Dec-2022, QC No AAJCER-22-85061; Revised: 13-Dec-2022, Manuscript No. AAJCER-22-85061 (R); Published: 20-Dec-2022, DOI:10.35841/aajcer-5.6.126

Citation: Ha C. Mammalian fetal stem cells with regular and preeclamptic births differentially produce vascular endothelial growth factor (VEGF), endocrine system. J Clin Endocrinol Res. 2022;5(6):126

Visit for more related articles at Journal of Clinical Endocrinology Research


Aberrant gestation disorders like hyperglycemia are linked to abnormal vascular growth and reduced endothelial function in fetal tissues. Endometriosis is a potentially fatal prenatal condition that is characterized by that of the start of albumin with a high blood pressure. Endometriosis affects 7 to 10% of pre pregnancies any, is one of the major causes of autoimmune preterm in babies, and is responsible for about 15% points of pregnancy-related mortality. Pre-clampsia'sclampsia's path hypothesize do physiology is hypothesized to in hypothesize solve the malfunction of endothelial cells, uterine hemorrhage, and abnormal organogenesis. One of these is thought to be a major contributing factor to hypertension, and that is endothelium insufficiency.


Hyperglycemia, Endometriosis, Hypothesized, Organogenesis, Hypertension.


A crucial controller of capillary development and function is vascular endothelial growth factor (VEGF). In mice, targeted disruption of a single VEGF mutation impairs heart function and results in neonatal death. There are least five glutamic acid versions of adult VEGF. The physiological effects and solubility of all these VEGF isoforms vary. For instance, VEGF121 is secreted readily form generating cells and doesn't engage fibrinogen. A sizeable portion of VEGF165 is still tightly attached to the extracellular matrix and cell surface, making it only partly mobile. VEGF121, 165, and 189 are the most often produced VEGF isoforms, while VEGF145, 183, or 206 are only produced in just few organs [1,2].

Additionally, VEGF165 has a stronger proliferative effect on vascular endothelium than VEGF121. Numerous VEGF forms being expressed in a single tissues and each having unique biochemical characteristics suggest that these isoforms play diverse functions in controlling vasculature function and growth [3]. The fact that mouse embryos who generate solely VEGF120 survive to term despite having significant vascular abnormalities lends weight to this. Furthermore, in relation to vascular formation, specialization, & functioning with in growing rodent organs, expression of each VEGF isoform varies over time and space.

A recently discovered coagulant factor known as neuroendocrine sensory organ VEGF (EG-VEGF) can promote the proliferation, migration, and fenestration of endothelial cells in capillaries that are specifically generated from adrenal gland. Hypoxia induces the expression of human EG-VEGF mRNA, which is only found in spermatogenic organs such as the uterus. Unfortunately, there is currently insufficient information to compare the expression of EG-VEGF in human placentas from normal pregnancy (PE) with gestations [4].

There seems to be disagreement about the evidence regarding VEGF expression in normal and PE babies. The bulk of such investigations evaluated the serum concentrations of VEGF in the maternal circulation and found that, primarily according on the methodology employed, concentrations were either lower or higher in normal pregnancies compared to PE pregnancies. Similar reports indicate that healthy whereas for PE pregnancy's placental VEGF mRNA levels either are lowered, raised, or unaffected. The protein expression of VEGF and VEGF receptors in placentas from healthy and Pathologic fetuses is still poorly understood. Thereby also, in just this survey we had also analyzed mRNA and peptide affirmation of vascular endothelial growth factor and also its four synapses as well as Such as mRNA appearance in intrauterine cells from regular and PE pregnant women to evaluate whether utterance of independent VEGF iso-enzymes and VEGF neurotransmitters in umbilical cords is connected with pregnancy complications [5].


Furthermore, scientists showed for the first time that PE placentas expressed more VEGFR-1 proteins than normal placentas did. In addition, we discovered that PE placentas had higher protein levels of two key VEGF isoforms than normal placentas, despite having higher mRNA levels of all three VEGF isoforms evaluated. Furthermore, we discovered the first time that there was no appreciable differences in the production of mRNAs and molecules for Example, VEGFR-2, NP-1, and NP-2 between PE and normal placentas, indicating that they might not particularly important in PE umbilical cords.


  1. Salenave S, Ancelle D, Bahougne T, et al. Macroprolactinomas in children and adolescents: Factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100(3):1177-86.
  2. Indexed at, Google Scholar, Cross Ref

  3. Arya VB, Aylwin SJB, Hulse T, et al. Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis. Clin Endocrinol. 2021;94(3):413-23.
  4. Indexed at, Google Scholar, Cross Ref

  5. Smith TR, Hulou MM, Huang KT, et al. Current indications for the surgical treatment of prolactinomas. J Clin Neurosci. 2015;22(11):1785-91.
  6. Indexed at, Google Scholar, Cross Ref

  7. Paepegaey AC, Salenave S, Kamenicky P, et al. Cabergoline tapering is almost always successful in patients with macroprolactinomas. J Endocr Soc. 2017;1(3):221-30.
  8. Indexed at, Google Scholar, Cross Ref

  9. Karavitaki N. Prevalence and incidence of pituitary adenomas. Ann Endocrinol. 2012;73(2):79-80.
  10. Indexed at, Google Scholar, Cross Ref

Get the App